Taiga Nishihori Selected Research

Autologous Transplantation

1/2022	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
12/2020	Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
1/2020	Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
1/2019	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
1/2018	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
1/2018	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure.
2/2017	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
11/2015	Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
11/2014	Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
11/2013	Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taiga Nishihori Research Topics

Disease

38	Graft vs Host Disease (Graft-Versus-Host Disease) 11/2022 - 02/2011
29	Neoplasms (Cancer) 10/2022 - 11/2002
27	Multiple Myeloma 12/2022 - 10/2011
19	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 10/2022 - 06/2014
14	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 10/2010
13	Lymphoma (Lymphomas) 12/2021 - 09/2013
12	Leukemia 10/2022 - 06/2015
9	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 01/2020
9	Infections 11/2021 - 09/2013
8	Bronchiolitis Obliterans Syndrome 11/2022 - 10/2010
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2022 - 03/2016
6	Plasma Cell Leukemia 07/2022 - 12/2011
6	Hematologic Neoplasms (Hematological Malignancy) 07/2021 - 01/2017
5	Cytokine Release Syndrome 01/2022 - 01/2020
4	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 12/2020 - 01/2016
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 11/2021 - 10/2015
3	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 10/2015
3	Pathologic Complete Response 01/2020 - 03/2016
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2020 - 11/2014
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2019 - 01/2018
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2018 - 06/2015
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 04/2022 - 05/2017
2	Amyloidosis 01/2022 - 11/2015
2	T-Cell Prolymphocytic Leukemia (Leukemia, T Cell, Chronic) 01/2022 - 01/2018
2	Immunoglobulin Light-chain Amyloidosis 01/2022 - 01/2022
2	Cytomegalovirus Infections (Inclusion Disease) 10/2021 - 01/2015
2	Cytopenia 01/2021 - 09/2013
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2021 - 01/2020
2	Primary Myelofibrosis (Myelosclerosis) 12/2020 - 11/2010
2	Thrombotic Microangiopathies 01/2020 - 09/2011
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 10/2015
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 05/2016 - 10/2015
1	POEMS Syndrome (Syndrome, POEMS) 12/2022
1	COVID-19 10/2022
1	Hemorrhage 01/2022
1	Cryptogenic Organizing Pneumonia 01/2022
1	Obesity 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	cell-associated neurotoxicity 01/2021

Drug/Important Bio-Agent (IBA)

14	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2022 - 10/2015
11	Tacrolimus (Prograf)FDA LinkGeneric 01/2022 - 12/2012
9	Melphalan (Alkeran)FDA LinkGeneric 11/2021 - 06/2012
8	Busulfan (Busulfex)FDA Link 11/2021 - 10/2010
8	Methotrexate (Mexate)FDA LinkGeneric 01/2019 - 12/2012
7	fludarabineIBA 11/2021 - 02/2011
7	axicabtagene ciloleucelIBA 01/2021 - 01/2020
7	Calcineurin InhibitorsIBA 01/2021 - 09/2011
6	GlucocorticoidsIBA 11/2022 - 10/2010
6	Bortezomib (Velcade)FDA Link 01/2022 - 06/2012
6	Rituximab (Mabthera)FDA Link 01/2020 - 02/2011
5	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 01/2014
5	Sirolimus (Rapamycin)FDA Link 01/2022 - 09/2011
5	Chimeric Antigen ReceptorsIBA 12/2021 - 01/2021
5	Lenalidomide (CC 5013)FDA Link 02/2017 - 09/2013
4	AntigensIBA 01/2021 - 09/2013
3	Mycophenolic Acid (Cellcept)FDA LinkGeneric 01/2021 - 01/2019
3	SteroidsIBA 01/2021 - 11/2014
3	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 01/2016
3	Alemtuzumab (Campath)FDA Link 01/2020 - 09/2013
3	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019 - 10/2015
2	ofatumumab FDA Link 11/2022 - 06/2015
2	InterferonsIBA 01/2021 - 10/2005
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 01/2021
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 01/2019 - 10/2015
2	Biological ProductsIBA 10/2017 - 01/2017
2	liposomal doxorubicin (Doxil)FDA Link 11/2015 - 01/2014
2	Glucose (Dextrose)FDA LinkGeneric 09/2015 - 02/2011
1	Prednisone (Sone)FDA LinkGeneric 11/2022
1	Oxygen (Dioxygen)IBA 10/2022
1	ixazomibIBA 07/2022
1	Tumor Biomarkers (Tumor Markers)IBA 01/2022
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2022
1	IgKIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	Immunoconjugates (Immunoconjugate)IBA 07/2021
1	CalcineurinIBA 01/2021
1	LigandsIBA 01/2021
1	Cephalosporins (Cephalosporin Antibiotics)IBA 01/2021
1	Ferritins (Ferritin)IBA 01/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	tisagenlecleucelIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021

Therapy/Procedure

96	Cell Transplantation 12/2022 - 10/2010
44	Therapeutics 11/2022 - 10/2005
29	Transplantation 10/2022 - 02/2011
17	Homologous Transplantation 07/2022 - 10/2010
15	Hematopoietic Stem Cell Transplantation 10/2022 - 11/2011
11	Drug Therapy (Chemotherapy) 01/2022 - 09/2015
11	Autologous Transplantation 01/2022 - 09/2013
4	Stem Cell Transplantation 01/2021 - 01/2019
3	Immunotherapy 07/2021 - 09/2013
2	Photopheresis 10/2017 - 11/2014
1	Artificial Respiration (Mechanical Ventilation) 10/2022
1	Donor Selection 03/2022
1	MDC protocol 01/2022
1	Salvage Therapy 01/2022
1	Aftercare (After-Treatment) 01/2021
1	Length of Stay 01/2021